Skip to main content
Oncoinvent ASA logo

Oncoinvent ASA — Investor Relations & Filings

Ticker · OCIN ISIN · NO0010779341 LEI · 54930076H5GUZRMSNR39 Euronext Growth Manufacturing
Open in API
Filings indexed 138 across all filing types
Latest filing 2025-04-28 Report Publication Anno…
Country NO Norway
Listing Euronext Growth OCIN

About Oncoinvent ASA

https://www.oncoinvent.com/

Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies for cancer. The company's core focus is on direct alpha therapy, a technology platform designed to deliver potent, short-range radiation directly to cancerous tumors. Its lead product candidate, Radspherin®, is composed of inorganic microparticles that carry the alpha-emitting radionuclide Radium-224. This formulation is engineered for regional retention and slow degradation, enabling a high radiation dose to be administered within the peritoneal cavity while minimizing systemic exposure. Oncoinvent's clinical programs are primarily investigating the use of Radspherin® for treating metastatic cancers in the peritoneal cavity, including ovarian and colorectal cancer.

Recent filings

Filing Released Lang Actions
Financial calendar
Report Publication Announcement Classification · 98% confidence The document text is extremely short (448 characters) and consists entirely of a 'Financial calendar' listing future dates for key corporate events like the Annual Report, Half-yearly Report, Annual General Meeting, and Quarterly Reports. It does not contain the content of any of these reports. Since it is an announcement detailing the schedule for future report publications, it best fits the 'Report Publication Announcement' (RPA) category, which covers announcements regarding the timing or release of company reports. It is not the report itself (like 10-K or IR).
2025-04-28 English
Oncoinvent ASA Announces Positive Safety Review of Lead-In Cohort, Advances to Randomised Part of Ongoing Phase 2 Trial of Radspherin® in Ovarian Cancer Patients
Regulatory Filings Classification · 100% confidence The document is a press release announcing a positive safety review for a clinical trial (Phase 2 of Radspherin®) and the subsequent initiation of the randomized part of that trial. This type of announcement, detailing clinical progress, trial updates, and operational milestones, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific operational update rather than a comprehensive financial report (10-K, IR) or a general announcement about a report being published (RPA), and it focuses on clinical trial progression which often accompanies earnings, it fits best as an Earnings Release (ER) if it's part of a periodic update cycle, or RNS if it's an ad-hoc regulatory disclosure. Given the nature of clinical trial updates being frequently bundled with earnings announcements, ER is a strong candidate. However, since it is a specific, non-financial operational update, and does not contain the typical structure of a full earnings release (like key financial metrics), RNS (Regulatory Filings - the fallback for miscellaneous regulatory/operational announcements) is the most appropriate classification for a specific, non-financial clinical trial milestone announcement that is not explicitly defined elsewhere. It is not a Call Transcript (CT), Investor Presentation (IP), or a formal financial report (10-K, IR). I will classify it as RNS as it is a specific operational announcement that doesn't fit the other categories perfectly.
2025-03-25 English
Oncoinvent ASA: Mandatory notification of trade
Director's Dealing Classification · 100% confidence The document explicitly states it is a 'Mandatory notification of trade' concerning a 'Primary insider' (Anne Cecile Alvik) acquiring shares. This type of filing, reporting personal share transactions by company directors and executives (insider trades), directly corresponds to the definition of Director's Dealing. The reference to EU regulation 596/2014 (MAR) Article 19 confirms this is an insider transaction disclosure. Therefore, the appropriate code is DIRS.
2025-03-05 English
Oncoinvent ASA: Fourth Quarter 2024 Update and Results
Interim / Quarterly Report Classification · 100% confidence The document is a '4th Quarter 2024' report for Oncoinvent ASA. It contains detailed operational reviews, clinical trial updates, corporate highlights, and a 'Key Financials' table with unaudited quarterly and annual data. Since it provides comprehensive financial and operational performance for a specific fiscal period (Q4 2024) and includes actual financial statements/data, it qualifies as an Interim/Quarterly Report. Q4 2024
2025-02-27 English
Oncoinvent ASA: Fourth Quarter 2024 Update and Results
Earnings Release Classification · 100% confidence The document is titled "Oncoinvent ASA: Fourth Quarter 2024 Update and Results" and provides key highlights and a detailed financial update for the 4th quarter, including revenues, EBITDA, and year-end figures. This structure—announcing period results with key operational and financial metrics—is characteristic of an Earnings Release (ER). Although it contains financial data, it is presented as an announcement/summary rather than a comprehensive, formal quarterly report (which would typically be classified as IR). Since it explicitly announces the results for a specific period (Fourth Quarter 2024), ER is the most appropriate classification. Q4 2024
2025-02-27 English
Oncoinvent ASA reports completed inclusion in the initial safety lead-in cohort of the phase 2 trial of Radspherin® in Ovarian Cancer Patients
Regulatory Filings Classification · 98% confidence The document is a press release from Oncoinvent ASA announcing the completion of patient inclusion in the initial safety lead-in cohort of a Phase 2 clinical trial for their drug Radspherin®. This type of announcement, detailing progress in clinical development, trial milestones, and future plans, is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is not a full financial report (10-K, IR), a specific management discussion (MDA), or a formal transcript (CT), and it is a direct announcement of operational progress, it fits best under the general category for corporate news releases that aren't explicitly covered elsewhere. Given the options, 'ER' (Earnings Release) is often used for significant operational updates, but 'RNS' (Regulatory Filings/General Regulatory Announcements) serves as a strong fallback for press releases detailing clinical trial milestones that aren't strictly financial results. However, because this is a specific operational update announcing a trial milestone and future expectations, and it is not a formal financial report, it is most appropriately classified as a general regulatory announcement or press release, which aligns with RNS, or potentially ER if it were tied to a quarterly cycle, but here it is purely operational news. Given the context of clinical trial progress announcements, RNS is the most suitable general category for non-financial, operational news releases.
2025-02-27 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.